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Abstract
Background: Some studies have shown evidence that the prophylactic use of bethanechol chloride (BC) may be 
useful in preventing the incidence and/or severity of xerostomia (XT). However, the indication of BC in irradiated 
patients with XT needs to be better characterized. The study aimed to evaluate the influence of BC on XT, salivary 
flow rate, and salivary composition in patients previously submitted to head and neck radiotherapy. 
Material and Methods: Forty five irradiated patients complaining of XT used 50 mg/day of BC for 3 months, and 
the salivary parameters were evaluated in 4 Phases (Before BC therapy, after one month of BC, 2 months of BC, 
and 3 months of BC). Biochemical analysis included buffering capacity; pH; total protein concentration (TP); 
amylase concentration (AM); catalase (CAT) and peroxidase (PX) activities. In addition, unstimulated and stimu-
lated salivary flow rates were determined and XT was classified. 
Results: According to the XT grading system used, patients showed improvement in XT between Phase 1, and 
Phases 2, 3 and 4. In addition, some changes were observed in TP concentration (decreased); AM concentration 
(increased); and PX and CAT activities (decreased and increased, respectively) after Phase 2, for stimulated saliva 
collection (p<0.05). 
Conclusions: Our results suggested that when BC was used to treat salivary gland dysfunction induced by head 
and neck radiotherapy, improvement in XT symptoms, and some changes in saliva composition were shown.
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Introduction
The radiotherapy (RT) is indicated as primary, adjuvant 
to surgery, or palliative therapy for tumors in the head 
and neck region (1). However, the secondary effects of 
the RT are a challenge to the professionals involved in 
the management of these patients. Oral mucositis; taste 
alterations; trismus; dental caries; progressive peri-
odontal disease; osteoradionecrosis; hyposalivation and 
xerostomia (XT) are the main disturbing side effects 
related to head and neck RT (2).
XT may cause an important impact on patients’ qual-
ity of life, mainly because it may last throughout their 
entire lifetime (3). Xerostomic patients usually present 
difficulties with chewing, swallowing, tasting or speak-
ing (4).
The mechanisms by which RT causes damage to the sal-
ivary glands have not yet been completely elucidated. 
Konings et al. (5) proposed that RT promotes injuries 
to the signal transduction system of cell membranes 
in salivary glands. Free radicals and peroxides bind to 
acinar cell membrane receptors, blocking activation of 
the entire intracellular protein signaling cascade. Thus, 
XT and hyposalivation are caused by impaired saliva 
production. Some authors (6,7), have suggested that the 
salivary flow is preserved when the doses of RT are be-
tween 26 Gy and 32 Gy; and Jensen et al. (8) related that 
a dose higher than 52 Gy causes a permanent damage to 
salivary glands. 
Bethanechol Chloride (BC), a cholinergic agonist, has 
been considered an option to increase the salivary flow 
rate during head and neck RT, because it has fewer side 
effects than pilocarpine (9,10). Recently, our group, in a 
double-blind study, demonstrated that the prophylactic 
use of BC improved the salivary flow rate, XT symp-
toms and quality of life of patients submitted to radio-
therapy (2). However, few studies have demonstrated 
the benefits of BC for treating salivary gland hypofunc-
tion in patients previously submitted radiotherapy in the 
head and neck regions. Thus, the aim of this study was 
to evaluate the effect of BC therapy on XT, hyposaliva-
tion and saliva composition in head and neck irradiated 
patients.
Material and Methods
This interventional study was conducted at the Uni-
versity of São Paulo from March 2013 to January 2015. 
The ethics committee approved this study (Nº 166.104) 
and written informed consent was obtained from all pa-
tients. All procedures performed in this study, involving 
human participants, were in accordance with the ethi-
cal standards of the institutional and national research 
committee and with the Helsinki Declaration of 1975 as 
revised in 1983.
- Patients
This interventional study enrolled 45 patients of the 
“Liga Interdisciplinar de Neoplasias Bucais” (LINB) of 
the University of São Paulo, who were submitted to head 
and neck RT with a minimal dose of 60Gys; and com-
plained of xerostomia. All the patients were assessed 
for eligibility. The grade of XT was evaluated monthly, 
from baseline to 3 months after treatment, using Eis-
bruch’ scale (11). Exclusion criteria were: patients with 
hypersensitivity to BC; hypotension; hyperthyroidism; 
peptic ulcer disease; epilepsy; angina; those with par-
kinsonism; smoking; patients using tricyclic antide-
pressant and antihistamine drugs.
- Study design 
This study was designed to test BC therapy after head 
and neck RT, therefore, the follow up time was 3 months, 
divided into four Phases: before BC administration 
(Phase 1) and after 1 (Phase 2), 2 (Phase 3) and 3 (Phase 
4) months. Phases 2, 3 and 4 were compared with Phase 
1 in all the statistical tests. According to the ethical 
principles Phase 1 (assessments before BC administra-
tion) was used as a control parameter for the subsequent 
Phases (after BC administration). The 3 months follow-
up was chosen according to the evidences and effective-
ness of BC treatment found in a similar study (2) and 
prophylactic treatment with agonists drugs, such as pi-
locarpine and bethanechol, have shown a positive effect 
on salivary flow in animals and humans within 30 days 
after radiotherapy (2,12).
- Bethanechol protocol: BC therapy consisted of one 
tablet twice a day for 3 months (50mg/day). Bethane-
chol toxicity was scored using National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
- NCI CTCAE, v3.0 (2,13). This questionnaire was 
designed to address specific acute and late symptom-
related toxicity experienced by cancer patients. Once a 
month, the questionnaire was applied to all patients, to 
control possible bethanechol-related symptoms. 
- Xerostomia: The grade of XT was assessed by a single 
professional, monthly from Phase 1 to Phase 4 using a 
grading system, according to the subjective measures of 
the Eisbruch et al. (11)  (2003) scale as follows: 
Grade 1: mild dryness with no disability.
Grade 2: dryness requiring additional fluids for swal-
lowing.
Grade 3: dryness causing dietary alterations, interfer-
ence with sleep, speaking or other activities.
To compute the correlation between XT and the Phases, 
mild XT was considered Grade 1 and severe XT, Grade 
2 or 3.
- Saliva collection
Sialometry was evaluated by unstimulated whole saliva 
(UWS) and stimulated whole saliva (SWS). Saliva was 
collected in all the experimental time intervals; always 
in the morning, between 8h30 a.m. and 11h30 a.m., to 
minimize the effects of the circadian rhythm in salivary 
glands. All patients were instructed not to eat, drink or 
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smoke 1 hour before saliva collection. In all types of 
collections, the patients were placed in a comfortably 
seated position and asked to swallow any saliva in the 
mouth, immediately before the tests. For the UWS, the 
patient started spitting the spontaneously produced 
saliva into a plastic funnel connected to a graduated 
tube, for 10 minutes. The last collection was SWS, 
using one drop of solution of citric acid on the dorsum 
of the tongue every 30 seconds for 10 minutes, then the 
patients were instructed to spit the saliva into another 
tube (14). After collection, the samples were weighed 
and the salivary flow rate was calculated and adjusted in 
ml/min (15). For samples in which a sufficient volume 
of saliva was acquired (> 0.5 ml) the pH and the Buffer 
Capacity evaluations were performed immediately after 
the UWS collections. (These tests could not be performed 
for SWS, due to the interference of citric acid.) After 
this, all the saliva samples were kept on crushed ice, and 
taken to the Oral Biology Laboratory of the University 
of São Paulo (USP), were the samples were centrifuged 
and then stored at -80ºC until biochemical analyses 
were performed (14). 
- Biochemical analyses 
pH and Buffer Capacity: To evaluate buffer capacity 
and pH, 0.5 mL of UWS samples were used to perform 
the pH analysis by means of a Digimed 2D portable pH 
meter, immediately after the saliva collections. After 
this, the buffer capacity was evaluated by titration of the 
sample with a HCl 0.01 N solution. Before measuring 
began, the pH meter was calibrated with standard pH 
solutions at the values 7.0 and 4.0. The buffer capacity 
was expressed by the quantity of HCl required to 
decrease the sample pH to 4.0.
Total protein concentration (TP): The TP in saliva was 
determined by the Lowry et al. (16) (1951) method, 
using bovine albumin as standard. The readouts were 
made at 660 nm by using an ELISA plate reader.
Amylase (AM): This was determined by Bellavia et 
al. (17) (1979) . The readouts were made at 530nm in a 
Beckman DU-68 spectrophotometer.
Peroxidase (PX) and Catalase activity (CAT): PX was 
determined according to Anderson (18) (1986) and 
Chandra et al. (19) (1977) (using a lactoperoxidase so-
lution as standard, and the absorbance was measured 
at 460 nm. The CAT activity was measured at 240nm 
in a Beckman DU-68 spectrophotometer, according to 
the methods of Aebi (20) (1984) . The difference in ab-
sorbance per unit time was the measure of the catalase 
activity.
- Statistical Analyses
Statistical analyses were performed using Minitab 16.1 
and MedCalc 15.2.2 software packages. The McNe-
mar test was applied to compare results of XT grades 
in each Phase. After this, Biochemical and Sialometry 
data were submitted to analysis of variance followed by 
2 sample T tests. All the results were obtained with a 
confidence interval of 95%.
Results
A total of 45 patients were assessed and all completed 
Phase 1; 41 completed Phase 2 (2 were excluded due to 
hypotension - a side effect of the BC; and 2 did not keep 
the appointment); 37 completed Phase 3 (4 did not keep 
the appointment); and 30 completed Phase 4 (a total of 
7 patients were excluded; 2 due to thyroid alteration; 1 
died; 2 due to recurrence of the tumor; and 2 did not 
keep the appointment). A total of 15 patients did not 
complete all Phases of the study (a side effect of BC was 
considered in only 2 patients) (Table 1). 
- Xerostomia evaluation:
During Phase 1 (before BC therapy), most of the patients 
had severe XT (93.3%); only 3 patients (6.7%) presented 
XT Grade 1. There was a gradual improvement in the 
grade of XT during the next 3 Phases of the study. In 
Phases 2, 3 and 4, the percentage of severe XT decreased 
to 80.5%, 75.7% to 70%, respectively. Inversely, mild 
XT increased from 19.5% (Phase 1), to 24.3% (Phase 2) 
and to 30% (Phase 3) (Fig. 1, Table 2) 
When mild XT was compared with severe XT, there 
was significant improvement between Phase 1 and 
others (Table 3). 
- Sialometry evaluation:
The sialometry results, for both UWS and SWS, showed 
Variables Category Patients (%)
Age (years) Mean
Range
56.44
16-76
Gender FemaleMale
16 (35.56)
29 (64.44)
Chemotherapy Yes
No
23 (51)
22 (49)
Surgery Yes
No
14 (31)
31 (69)
Type of RT
IMRT
3D
2D
9 (20)
23 (51)
13(29)
RT dose (Gys) Mean
Range
65.6
60-70
*Time (months) Mean
Range
21.1
1-88
Tumor site
Mouth
Oropharynx
Nasopharynx
Parotid
Larynx
Others
15 (33.3)
20 (44.4)
4 (8.8)
2 (4.4)
3 (6.7)
1 (2.2)
Table 1. Clinical features of the 45 patients.
* Time between the end of RT and the beginning of the BC ther-
apy.
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no significant differences in the experimental time 
intervals (Phase 1 to 4) (Table 4).
- Biochemical analyses:
Buffer capacity and pH values showed no significant 
difference between the Phases (Table 4). However, 
saliva composition (both UWS and SWS) showed the 
following differences:
Total Protein: In UWS, the TP test showed no difference 
between the Phases (Table 4). Whereas for SWS 
collection, TP fluctuated: an increase between Phases 
1 and 2 (p<0.0001); decrease between Phases 1 and 3 
(p<0.0001); Phase 4, showed a return to values similar 
to those in Phase 1 (p=0.51) (Table 4). 
Peroxidase: In UWS collection, there was a decrease 
in PX activity by comparing Phase 1 with Phase 2 
(p=0.026); 3 (p=0.007) and 4 (p=0.018) (Table 4). 
For SWS, there also was a decrease in this enzyme 
activity, by comparing Phase 1 with the other Phases; 2 
(p=0.003); 3(p=<0.0001); and 4 (p=0.003) (Table 4).
Catalase: In UWS, there was no significant difference 
between the study Phases (p<0.05) (Table 4). However, 
in SWS, it was found an increase in CT when comparing 
Phase 1 with Phases 3 (p<0.0001) and 4 (p=0.003) 
(Table 4).
Amylase: There was an increase of AM concentration in 
UWS collection between the Phases 1 and 2(p=0.002); 
3 (p<0.0001) and 4 (p=0.029); (Table 4). For SWS 
collection, Phase 1 was compared to the others Phases 
(p<0.0001) (Table 4). 
Phase
Mild XT 
(Grade 1)
Severe XT
Grade 2 Grade 3
N (%) N (%) N (%)
1 (n=45) 3 (6.7) 13 (28.9) 29 (64.4)
2 (n=41) 8 (19.5) 12 (29.3) 21 (51.2)
3 (n=37) 9 (24.3) 10 (27) 18 (48.7)
4 (n=30) 9 (30) 7 (23.3) 14 (46.7)
Fig. 1. Distribution of the patients according to xerostomia grades in all phases.(Microsoft 
Excel 2007).
Table 2. XT Grades (Eisbruch et al. 2003) distributed in each Phase of the study.
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Discussion
Recently, our group demonstrated the benefits of BC 
used as prophylactic therapy to prevent radiotherapy-
induced XT, mainly in patients treated with IMRT. 
However, in some patients their XT scores increased 
after they stopped taking the drug, therefore the dura-
tion of BC administration needs to be better defined (2). 
In the present study, all patients had been treated with 
high doses of RT for head and neck cancers, and the 
action of BC was evaluated. There is no fully effective 
therapy for the treatment of XT. Artificial saliva, oral 
lubricants and pilocarpine are commonly used (12,21). 
Some patients still prefer to drink water constantly be-
cause they do not adapt to such therapies. Thus, the use 
of BC could benefit these previously irradiated patients, 
with minimal side effects. 
Cholinergic agonists have often been studied for the 
treatment of salivary glands damaged by RT (12). BC 
has an action similar to that of pilocarpine: both are 
cholinergic agonists and increase glandular function 
by stimulating the muscarinic and nicotinic receptors 
(22). However, as an advantage, BC has fewer side ef-
fects than pilocarpine (9,10,23). Epstein et al. (9) (1994) 
showed a significant increase in both UWS (p=0.003) 
and SWS (p=0.001) after BC therapy in irradiated pa-
tients. Later, Grosky et al. (10) (2004) compared BC and 
pilocarpine in 42 patients with XT after RT and both 
drugs showed statistically significant increase in SWS 
(p=0.01). Jham et al. (23) (2007) found an increase of 
UWS immediately after RT (p = 0.03). In a recent dou-
ble-blind study, our group showed that the prophylactic 
use of BC during the RT showed significant efficacy 
in preventing severe XT (p<0.001) and hyposalivation 
(p<0.05) (2). In the present study, we found a substantial 
reduction in XT Grade 3 (severe) from Phase 1 (64.4%) 
to Phase 4 (46.7%). However, it was not possible to find 
significant differences in the salivary flow rate. 
RT affects the composition and the quality of saliva, 
and pH values are known to be reduced to acidic levels 
after the RT, due to the reduction in bicarbonate levels 
(24). However, in this study, BC therapy was unable to 
improve the buffering capacity and pH of saliva in these 
patients. Hannig et al. (25) (2006) reported that the 
RT may influence the salivary protein concentrations, 
mainly shown in reduced proline-rich proteins, proba-
bly due to the loss of biological activity for maintaining 
oral health. The present study also found a change in TP 
concentration, in all the Phases, but it is not possible in-
fer which proteins were affected and whether this effect 
of fluctuation was caused by RT or BC.
Moreover, PX concentration decreased in all Phases 
of the study and CAT increased after Phase 3 in SWS. 
These results showed a natural loss of antioxidant ca-
pacity of saliva after RT (12) and BC was not capable of 
increasing these levels. Furthermore, the free radicals 
and peroxides produced in RT (5) may be responsible 
for the variation in TP and change in salivary enzyme 
activity, especially CAT and PX. The amylase concen-
tration also increased, indicating that the BC could 
stimulate the remnant acinar cells in irradiated patients, 
mainly the parotid gland cells.
This body of evidence was brought up for discussion 
Phases
Phase 1
Total of 
patients
IC 
95%
P1 P2
Severe Mild
Phase 
2
Severe
Mild
33
6
0
2 41
1.2-
14.6 0.031 0.034
Phase 
3
Severe
Mild
28
7
0
2 37
3.4-
18.9
0.016 0.042
Phase 
4 SevereMild
21
7
0
2 30
4.2-
23.3 0.016 0.082
Table 3. Contingency table for the phase 1 XT grades (Eisbruch et al. 2003) compared to the other 
phases (2, 3 and 4). For this association, the phase 1 was paired to each phase. 
p1: McNemar test for paired proportions (p<0.05); p2: adjusted p value for McNemar test.
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UWS Collection
Variables
Phases (n)
p1 p2 p3
1 2 3 4 
    UWS (mg/min)
0.04 + 
0.08 (45)
0.05 + 0.1 
(41)
0.05 + 
0.1 (37)
0.05+ 0.1 
(30) 0.522 0.564 0.501
pH
6.5 + 0.4 
(13)
6.7 + 0.4 
(10)
6.4 + 0.5 
(14)
6.4 + 0.4 
(9)
0.241 0.866 0.318
Buffer Capacity (ul)
700 + 
289.2 
(13)
840 + 
245.9 (10)
862 + 
287.3 
(14)
733.3 + 
331.7
 (9)
0.241 0.175 0.809
Total Protein (mg-
prot/ml)
8.3 + 
4.2 (8)
8.6 + 4.2 
(7)
8.1 + 3.6 
(9)
5.1 + 1.9 
(9)
0.924 0.897 0.078
Peroxidase (uglact/
mgprot) 
52 + 12 
(4)
26.6 + 
13.8 (5)
19.9 + 
9.3 (5)
23 + 14 
(5)
0.026 0.007 0.018
Catalase 
(U/mgprot) 
0.8 + 0.3 
(7)
0.8 + 0.6 
(5)
0.9 + 0.6 
(6)
0.6 + 0.4 
(6) 0.922 0.534 0.375
Amylase
(mgmaltose/mgprot)
0.9 + 0.6
(5)
5.6 + 2.2
(5)
3.4 + 0.8
(6)
2.6 + 1.3 
(5)
0.002 < 0.0001 0.029
SWS Collection
Variables
Phases (n)
p1 p2 p3
1 2 3 4 
SWS (mg/min)
0.2 + 
0.2
(45)
0.2 + 
0.3 (41)
0.2 + 
0.2 (37) 0.2 + 0.3 (30) 0.401 0.438 0.829
Total Protein (mg-
prot/ml)
7.7 + 
2.6 (16)
14.1 +  
5.6 (16)
3.6 + 1.7 
(14) 8.27 + 3 (16)
< 
0.0001
< 
0.0001 0.51
Peroxidase (uglact/
mgprot) 
41 + 16 
(9)
19.9 + 
13.2 
(13)
19.3 + 
7.6 (15)
21.4 + 9.5 
(11) 0.003
< 
0.0001 0.003
Catalase 
(U/mgprot) 
0.58 + 
0.27 
(18)
0.49 
+ 0.18 
(12)
1.56 + 
0.66 (11)
1.03 + 0.51 
(15)
0.323 < 0.0001 0.003
Amylase
(mgmaltose/mgprot)
1.52 + 
0.48 
(13)
3.15 + 
1.31 
(12)
18.67 + 
9.85 (8)
7.47 + 2.32 
(8)
< 
0.0001
< 
0.0001
< 
0.0001
Table 4. Mean of salivary flow unstimulated whole saliva (UWS) and stimulated whole saliva (SWS). pH and Buffer Capacity (for 
UWS), Total Protein, Peroxidase, Catalase and Amylase, compared in each phase of the study.
p1: Comparison between Phase 1 and Phase 2; p2: Comparison between Phase 1 and Phase 3; p3: Comparison between Phase 1 and 
Phase 4. Significant p value: p<0.05.
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with regard to the most opportune time to start BC ther-
apy, concomitantly or after RT. The model of free radi-
cals and peroxides that bind to acinar cell membrane 
receptors, blocking the activation of the entire intracel-
lular protein signaling cascade in salivary glands (5), 
could justify the best time for BC therapy. When BC 
binds to the receptors of the salivary gland cells as a 
cholinergic agonist, before RT, it could prevent the per-
oxides and free radicals produced by RT from binding 
in a way similar to that of a competitive mechanism. 
Thus, the best protocol for BC therapy seems to be the 
prophylactic approach, as has been stated in the litera-
ture (2,9,10,12,21,23). However, additional studies are 
necessary to prove this hypothesis and assess other pos-
sible changes in saliva composition, salivary flow rate 
and XT, especially in parotid glands. 
Miah et al. (26) evaluated the parotid gland function in 
irradiated patients by the Lashley method, which con-
sists in cups applied over the parotid ducts. Approxi-
mately 22% of the patients presented a pre-RT parotid 
salivary flow rate of 0.08 ml/min unstimulated and 0.1 
ml/min stimulated. One year after RT, both unstimu-
lated and stimulated parotid flows were 0.0 ml/min. In 
addition, some patients reported discomfort during the 
collection. In this study, a specific collection of parotid 
gland was not performed due to the flow reduction after 
RT that would prejudice substantially the sample volume 
and consequently the biochemical analysis. Most of the 
patients had completed the RT a long time ago (mean of 
21 months) and the hyposalivation was evaluated through 
UWS and SWS. Moreover, we used this methodology in 
a previous study (2) and the patients did not complain.
In conclusion, BC therapy used as treatment of XT in 
patients submitted to head and neck RT, could be im-
portant in decreasing the levels of this symptom, but 
not effective as prophylactic BC therapy. The substan-
tial increase in Amylase concentration suggests that BC 
stimulates the remnant parotid cells that were not af-
fected by RT.
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